Technical Analysis for MRTX - Mirati Therapeutics, Inc.
| ADX | Long-Term | Intermediate-Term | Short-Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| See historical MRTX trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Mar 19 | MACD Bearish Signal Line Cross | Bearish | 0.00% |
| Mar 19 | 20 DMA Support | Bullish | 0.00% |
| Mar 19 | Slingshot Bullish | Bullish Swing Setup | 0.00% |
| Mar 18 | Shooting Star Candlestick | Bearish | -4.06% |
| Mar 18 | MACD Bullish Signal Line Cross | Bullish | -4.06% |
| Mar 18 | Doji - Bearish? | Reversal | -4.06% |
| Mar 18 | New 52 Week High | Strength | -4.06% |
| Mar 18 | Upper Bollinger Band Touch | Strength | -4.06% |
| Mar 15 | 180 Bullish Setup | Bullish Swing Setup | -4.09% |
| Mar 15 | Earnings Movers | Other | -4.09% |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 2019-03-14
Mirati Therapeutics Inc., a biopharmaceutical company, engages in the development of therapeutics for the cancer treatment. Its lead program in clinical development is MGCD265, a multi-targeted small molecule kinase inhibitor for treatment of oncology patients with solid tumors. The company also evaluates development opportunities in oncology for mocetinostat, a spectrum-selective HDAC inhibitor for the treatment of patients with myelodysplastic syndrome or lymphoma; and MGCD516, a kinase inhibitor with a target profile for the treatment of patients with non-small cell lung cancer and other solid tumors. Mirati Therapeutics Inc. is headquartered in San Diego, California.
Medicine Biopharmaceutical Cancer Chemical Compounds Solid Tumors Oncology Non Small Cell Lung Cancer Lymphoma Cancer Treatment Targeted Therapy Myelodysplastic Syndrome Bemcentinib
Medicine Biopharmaceutical Cancer Chemical Compounds Solid Tumors Oncology Non Small Cell Lung Cancer Lymphoma Cancer Treatment Targeted Therapy Myelodysplastic Syndrome Bemcentinib
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength | |||
| Summary: | Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies. | ||
See more MRTX news...
Indicators
| Indicator | Value |
|---|---|
| 52 Week High | 80.0 |
| 52 Week Low | 24.65 |
| Average Volume | 745,489 |
| 200-Day Moving Average | 52.8058 |
| 50-Day Moving Average | 68.4136 |
| 20-Day Moving Average | 73.188 |
| 10-Day Moving Average | 71.779 |
| Average True Range | 3.9153 |
| ADX | 32.95 |
| +DI | 27.8215 |
| -DI | 18.6919 |
| Chandelier Exit (Long, 3 ATRs ) | 68.2541 |
| Chandelier Exit (Short, 3 ATRs ) | 76.7959 |
| Upper Bollinger Band | 79.7692 |
| Lower Bollinger Band | 66.6068 |
| Percent B (%b) | 0.5 |
| BandWidth | 17.984369 |
| MACD Line | 1.7446 |
| MACD Signal Line | 1.8524 |
| MACD Histogram | -0.1078 |
| Fundamentals | Value |
|---|---|
| Market Cap | 1.83 Billion |
| Num Shares | 25 Million |
| EPS | -3.38 |
| Price-to-Earnings (P/E) Ratio | -21.65 |
| Price-to-Sales | 0.00 |
| Price-to-Book | 3.81 |
| PEG Ratio | 0.00 |
| Dividend | 0.00 |
| Dividend Yield | 0.00% |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 80.63 | ||||
| Resistance 3 (R3) | 81.06 | 79.00 | 79.39 | ||
| Resistance 2 (R2) | 79.00 | 77.11 | 78.79 | 78.98 | |
| Resistance 1 (R1) | 76.10 | 75.94 | 75.07 | 75.67 | 78.56 |
| Pivot Point | 74.04 | 74.04 | 73.53 | 73.83 | 74.04 |
| Support 1 (S1) | 71.14 | 72.15 | 70.11 | 70.71 | 67.82 |
| Support 2 (S2) | 69.08 | 70.98 | 68.87 | 67.40 | |
| Support 3 (S3) | 66.18 | 69.08 | 66.99 | ||
| Support 4 (S4) | 65.75 |
